Education
About Us
Working with TipRanks
Follow Us
Achieve Life Sciences Inc (ACHV)
NASDAQ:ACHV
ACHV Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.84 - $5.31
Previous CloseN/A
Volume131.37K
Average Volume (3M)1.07M
Market Cap
$124.70M
Enterprise Value$32.95M
Total Cash (Recent Filing)$23.25M
Total Debt (Recent Filing)$9.96M
Price to Earnings (P/E)―
Beta1.52
Next Earnings
Nov 06, 2025EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.37
Shares Outstanding51,104,970
10 Day Avg. Volume651,496
30 Day Avg. Volume1,067,806
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.26
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-578.09
Enterprise Value/Ebitda-1.04
Forecast
1Y Price Target
$15.25Price Target Upside500.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Clinical StudiesThe submission of the NDA for cytisinicline as a treatment for smoking cessation is supported by positive data from both P3 ORCA-2 and ORCA-3 studies, demonstrating significantly higher quit rates.
Market DemandA notable 7 in 10 smokers want to quit, indicating a strong market demand for effective cessation aids.
Strategic PartnershipsA strategic partnership with Omnicom to co-develop and execute a fully integrated, AI-enabled US launch strategy for cytisinicline has been announced, pending FDA approval.
Bears Say
Market CompetitionThe discussion emphasized the lack of novel treatments for nicotine dependence in nearly 20 years, underscoring the potential impact of cytisinicline.
Operational CostsAn increase in 2025 and 2026 expense estimates, suggesting higher operational costs for the company in the coming years.
Regulatory TimelineACHV is still on track to submit cytisinicline's NDA in June 2025.
Achieve Life Sciences News
ACHV FAQ
What was Achieve Life Sciences Inc’s price range in the past 12 months?
Achieve Life Sciences Inc lowest stock price was $1.84 and its highest was $5.31 in the past 12 months.
What is Achieve Life Sciences Inc’s market cap?
Achieve Life Sciences Inc’s market cap is $124.70M.
When is Achieve Life Sciences Inc’s upcoming earnings report date?
Achieve Life Sciences Inc’s upcoming earnings report date is Nov 06, 2025 which is in 84 days.
How were Achieve Life Sciences Inc’s earnings last quarter?
Achieve Life Sciences Inc released its earnings results on Aug 07, 2025. The company reported -$0.37 earnings per share for the quarter, missing the consensus estimate of -$0.366 by -$0.004.
Is Achieve Life Sciences Inc overvalued?
According to Wall Street analysts Achieve Life Sciences Inc’s price is currently Undervalued.
Does Achieve Life Sciences Inc pay dividends?
Achieve Life Sciences Inc does not currently pay dividends.
What is Achieve Life Sciences Inc’s EPS estimate?
Achieve Life Sciences Inc’s EPS estimate is -0.24.
How many shares outstanding does Achieve Life Sciences Inc have?
Achieve Life Sciences Inc has 51,104,970 shares outstanding.
What happened to Achieve Life Sciences Inc’s price movement after its last earnings report?
Achieve Life Sciences Inc reported an EPS of -$0.37 in its last earnings report, missing expectations of -$0.366. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Achieve Life Sciences Inc?
Currently, no hedge funds are holding shares in ACHV
Achieve Life Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.25 (500.39% Upside)
$15.25 (500.39% Upside)
Blogger Sentiment
Bullish
ACHV Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.0%
Last 30 Days ▲ 401.5%
Last 30 Days ▲ 401.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.77%
12-Months-Change
Fundamentals
Return on Equity
-120.11%
Trailing 12-Months
Asset Growth
-9.04%
Trailing 12-Months
Company Description
Achieve Life Sciences Inc
Achieve Life Sciences, Inc. (ACHV) is a clinical-stage pharmaceutical company dedicated to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction. Operating primarily within the biopharmaceutical sector, the company's core focus is on addressing the global smoking health crisis by providing an alternative to existing smoking cessation therapies.
ACHV Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlights significant progress with the NDA submission, strategic partnerships, and strong financial positioning. However, the lengthy timeline for product launch and operational expenses present challenges. Overall, the positive advancements are substantial, but there are notable concerns about the approval timeline and expenses.View all ACHV earnings summariesACHV Stock 12 Month Forecast
Average Price Target
$15.25
▲(500.39% Upside)
Technical Analysis
Ownership Overview
0.44% Insiders
6.97% Mutual Funds
0.04% Other Institutional Investors
86.69% Public Companies and Individual Investors